Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
Aberdeen Group plc significantly increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 21.3% in Q3, now holding 339,949 shares valued at $14.16 million, representing about 0.36% of the company. Institutional investors collectively own 98.51% of Crinetics Pharmaceuticals. Analyst sentiment for CRNX is a "Moderate Buy" with a consensus target price of $75.78, despite some mixed ratings.
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug
Analysts are bullish on Crinetics Pharmaceuticals (CRNX) following positive clinical trial results for its congenital adrenal hyperplasia treatment and strong initial sales for its FDA-approved acromegaly drug, Palsonify. Stifel, Piper Sandler, and Goldman Sachs have all maintained or upgraded their ratings and raised price targets for CRNX, citing successful Phase 2 trial outcomes and better-than-expected fourth-quarter performance. The company specializes in developing novel therapeutics for rare endocrine diseases.
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday
Crinetics Pharmaceuticals (CRNX) is anticipated to release its Q4 2025 earnings after market close on Thursday, February 26, 2026, with analysts forecasting an EPS of ($1.35) and revenue of $4.323 million. The stock recently opened at $43.45, and while analyst ratings are mixed, the average sentiment is a "Moderate Buy" with a target price of $75.78. Insider Isabel Kalofonos recently sold 2,500 shares, and institutional investors hold approximately 98.5% of the company's stock.
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug
Analysts are expressing strong confidence in Crinetics Pharmaceuticals Inc. (CRNX) following positive developments in its clinical trials and drug launches. Stifel raised its price target to $84, Piper Sandler maintained a Buy rating with a $97 target, and Goldman Sachs upgraded its rating to Buy based on encouraging Phase 2 results for a congenital adrenal hyperplasia treatment. The company is actively developing novel therapeutics for rare endocrine diseases.
13 Hot Stocks to Buy with the Highest Upside Potential
The article highlights Crinetics Pharmaceuticals Inc. (CRNX) as one of 13 hot stocks with high upside potential, noting its 67.36% potential upside and 31 hedge fund holders. Recent analyst upgrades and positive clinical trial results for its congenital adrenal hyperplasia treatment are cited as key drivers for its optimistic outlook. The company specializes in developing therapeutics for rare endocrine diseases.
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT)
LifeSci Capital and TD Cowen analysts have issued bullish sentiments on Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT), respectively. Crinetics Pharmaceuticals received a Buy rating with a $97.00 price target, suggesting a 102.7% upside, while Abbott Laboratories also maintained a Buy rating with a $137.00 price target, indicating a 24.1% upside from current levels.
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT)
Two analysts have issued bullish ratings for healthcare companies Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT). LifeSci Capital analyst Kate Dellorusso maintained a Buy rating on Crinetics Pharmaceuticals with a $97.00 price target, while TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories with a $137.00 price target. Both companies are receiving "Strong Buy" consensus ratings from analysts.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded Crinetics Pharmaceuticals (CRNX) from a "hold" to a "sell" rating. Despite this, the broader analyst consensus remains "Moderate Buy" with an average price target of $82.50, based on ten "Buy" ratings and one "Sell" rating. Shares opened at $42.70, and the company has a market capitalization of $4.36 billion.
Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX
Candriam S.C.A. significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 7.4% in the third quarter, bringing their total holdings to 745,094 shares valued at approximately $31.0 million. Institutional investors now own about 98.51% of the company. Wall Street analysts maintain a "Moderate Buy" consensus rating for CRNX with an average target price of $82.50, despite an insider selling 2,500 shares in January.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $82.50. While some firms like Goldman Sachs and Morgan Stanley have upgraded or raised price objectives, others like Weiss Ratings maintain a "sell." The company recently missed its quarterly EPS estimates and an insider sold a significant number of shares, yet institutional investors have largely increased their holdings.
Liquidity Mapping Around (CRNX) Price Events
This article provides an AI-powered liquidity analysis for Crinetics Pharmaceuticals Inc. (CRNX), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels. The report emphasizes the exceptional 51.1:1 risk-reward short setup for CRNX, targeting a 15.2% downside.
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Crinetics Pharmaceuticals announced its participation in two upcoming investor conferences in March 2026. Management will attend the TD Cowen 46th Annual Health Care Conference and the Leerink Annual Global Healthcare Conference, with opportunities for fireside chats and one-on-one meetings with investors. The company, focused on endocrine diseases, highlights its lead product PALSONIFY™ for acromegaly and its pipeline including atumelnant and CRN09682.
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Crinetics Pharmaceuticals, Inc. announced its participation in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Annual Global Healthcare Conference. Management will hold a fireside chat and be available for one-on-one meetings with investors. The company, focused on endocrine diseases, will discuss its lead product PALSONIFY™ and other pipeline candidates.
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK)
Three analysts have issued bullish sentiments on several healthcare stocks, including Crinetics Pharmaceuticals (CRNX), Stryker (SYK), and Neurocrine (NBIX). Stifel Nicolaus maintained a Buy rating on Crinetics with an $84.00 price target, while Citi reiterated a Buy rating on Stryker. Neurocrine also received a reiterated Buy rating from Stifel Nicolaus, with an average price target indicating a significant upside.
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities By Investing.com
Crinetics Pharmaceuticals has updated Jeff Knight's executive title from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, reflecting his expanded responsibilities without changes to his compensation. The biopharmaceutical company maintains a strong financial position and has recently announced the dosing of the first patient in its BALANCE-CAH Phase 2/3 trial and priced a public offering to raise approximately $350 million. These developments, along with positive analyst ratings, indicate ongoing progress and interest in Crinetics' pharmaceutical advancements.
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals announced it will report its fourth quarter and full year 2025 financial results on February 26, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Crinetics focuses on developing novel therapies for endocrine diseases and endocrine-related tumors, with its lead product PALSONIFY™ already approved for acromegaly.
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals, Inc. will report its fourth-quarter and full-year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 4:30 p.m. ET. The company, known for its lead product PALSONIFY™ for acromegaly, has a pipeline of over ten programs for various endocrine diseases and related tumors. The announcement highlights potential positives such as transparency and innovation, but also notes the lack of financial guidance and specific product launch timelines.
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals, Inc. announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Crinetics Pharmaceuticals is focused on developing novel therapies for endocrine diseases and endocrine-related tumors, with their lead product PALSONIFY™ already approved by the U.S. FDA.
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after market close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update. Crinetics Pharmaceuticals focuses on developing novel therapies for endocrine diseases and endocrine-related tumors, with their lead product PALSONIFY™ already approved by the U.S. FDA for specific acromegaly patients.
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities
Crinetics Pharmaceuticals has updated Jeff Knight's title from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, without changing his compensation. This change reflects his expanded responsibilities within the $5.45 billion biopharmaceutical company, which has a strong financial position. The company also recently began a Phase 2/3 trial for atumelnant and successfully priced a public offering.
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities
Crinetics Pharmaceuticals announced a change in Jeff Knight's executive title from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, reflecting his current responsibilities. The biopharmaceutical company, valued at $5.45 billion, noted no changes to Knight's compensation. This update follows other recent company news, including the dosing of the first patient in its BALANCE-CAH Phase 2/3 trial and a public offering to raise $350 million.
Why (CRNX) Price Action Is Critical for Tactical Trading
This article from Stock Traders Daily analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide tactical trading insights. It highlights weak near-term sentiment with potential shifts, identified resistance levels, and an exceptional risk-reward short setup. The analysis offers specific institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging.
Jim Cramer on Crinetics: “That’s a better spec than Aquestive”
NULL
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 13.5%, now holding 387,925 shares valued at $16.16 million, as institutional investors own approximately 98.51% of the stock. While many analysts maintain a "Moderate Buy" rating with an average target of $82.50, the company has seen recent insider stock sales and missed EPS estimates, trading at $53.18 with a $5.05 billion market cap and a negative P/E ratio. Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare endocrine diseases.
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists
Crinetics Pharmaceuticals has initiated dosing in its Phase 2/3 BALANCE-CAH trial for atumelnant, targeting classic congenital adrenal hyperplasia in pediatric patients. Atumelnant, an oral ACTH receptor antagonist with Orphan Drug Designation, represents a significant clinical catalyst for the company. Despite positive stock performance, Simply Wall St suggests a valuation gap, with the stock trading below its estimated fair value.
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists
Crinetics Pharmaceuticals has initiated dosing pediatric patients in its Phase 2/3 BALANCE-CAH trial for atumelnant, targeting classic congenital adrenal hyperplasia. Atumelnant, an oral ACTH receptor antagonist with Orphan Drug Designation, represents a late-stage asset in the company's endocrinology pipeline. Despite significant past stock price appreciation, Simply Wall St suggests a substantial valuation gap, highlighting the company's current unprofitability and dependence on successful clinical and regulatory outcomes for atumelnant.
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists
Crinetics Pharmaceuticals has initiated dosing for pediatric patients in its Phase 2/3 BALANCE-CAH trial for atumelnant, targeting classic congenital adrenal hyperplasia. Atumelnant, an oral ACTH receptor antagonist with FDA Orphan Drug Designation, represents a significant clinical catalyst for the company. Despite an impressive stock performance, Simply Wall St suggests the company's valuation still shows a significant gap, trading well below its estimated fair value and analyst targets.
Crinetics begins phase 2/3 trial of oral CAH treatment in children
Crinetics Pharmaceuticals has initiated a Phase 2/3 trial (BALANCE-CAH) for atumelnant, an oral treatment for congenital adrenal hyperplasia (CAH) in children, marking a significant step in addressing an unmet medical need. The company's shares are performing well, and analysts are optimistic about its prospects, reinforced by strong financial health and recent positive developments for its other product, Palsonify. Atumelnant, designated as an Orphan Drug, is the first and only small molecule ACTH receptor antagonist in late-stage clinical development for CAH.
New trial tests once-daily pill for rare adrenal disorder in kids
Crinetics Pharmaceuticals has initiated a Phase 2/3 pediatric trial (BALANCE-CAH) for atumelnant, a once-daily oral ACTH receptor antagonist, for children and adolescents with classic congenital adrenal hyperplasia (CAH). This potential registrational study will assess the drug's safety, efficacy, and pharmacokinetics in a population with significant unmet medical need. Atumelnant has received U.S. orphan drug designation for classic CAH and is the first and only small molecule ACTH receptor antagonist in late-stage clinical development.
Crinetics begins phase 2/3 trial of oral CAH treatment in children
Crinetics Pharmaceuticals has initiated a Phase 2/3 clinical trial (BALANCE-CAH) for atumelnant, an oral treatment for congenital adrenal hyperplasia (CAH) in children and adolescents. The company highlighted atumelnant as the first small molecule ACTH receptor antagonist in late-stage development for CAH. Crinetics maintains a strong financial position and has received Orphan Drug Designation for atumelnant, with analysts showing optimism for its prospects.
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains?
Crinetics Pharmaceuticals (CRNX) has shown significant share gains over several years, leading investors to question its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 88.7%, despite recent excellent performance. However, its Price-to-Book (P/B) ratio of 5.30x is above the industry average but within its peer group.
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pediatric Patients
Crinetics Pharmaceuticals (CRNX) has commenced its BALANCE-CAH Phase 2/3 clinical trial for atumelnant, an oral therapy for classic congenital adrenal hyperplasia in pediatric patients. Despite financial challenges like negative revenue growth and operating margins, the biotechnology company maintains a strong balance sheet with high liquidity and low debt. However, valuation metrics suggest overvaluation, and insider selling has been observed.
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals has initiated the BALANCE-CAH Phase 2/3 trial to evaluate atumelnant, a novel ACTH receptor antagonist, for the treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents. This study aims to address a significant unmet medical need by correcting elevated androgen levels with low glucocorticoid doses to support normal growth and development. Atumelnant, which recently received Orphan Drug Designation, is the first small molecule ACTH receptor antagonist in late-stage clinical development for this condition.
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals has begun a Phase 2/3 pediatric trial, BALANCE-CAH, for its investigational drug atumelnant, an ACTH receptor antagonist, to treat classic congenital adrenal hyperplasia (CAH) in children and adolescents. This aims to address the significant unmet medical need in this population by correcting elevated androgen levels while allowing for low glucocorticoid doses. Atumelnant has received Orphan Drug Designation and is the first small molecule ACTH receptor antagonist in late-stage clinical development for CAH, with promising results from a previous Phase 2 study.
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains?
Crinetics Pharmaceuticals (CRNX) has seen significant share gains, with a 282.9% increase over five years. A Discounted Cash Flow (DCF) analysis suggests the stock is currently 88.7% undervalued at $55.41 per share, with an estimated intrinsic value of $491.04. However, its Price-to-Book (P/B) ratio of 5.30x is higher than the industry average, indicating the market is valuing its future growth and pipeline.
Jim Cramer on Crinetics: "That's a Better Spec Than Aquestive"
Jim Cramer endorsed Crinetics Pharmaceuticals (CRNX) as a better speculative investment than Aquestive, citing a recent "Buy" recommendation from Goldman Sachs. He emphasized focusing on a company's quality rather than its stock price. Crinetics develops oral drugs for rare hormonal diseases and tumors, with its lead candidate, Paltusotine, in Phase 3 trials, but the article suggests that certain AI stocks may offer greater upside potential with less risk.
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive”
Jim Cramer recently recommended Crinetics Pharmaceuticals (NASDAQ: CRNX) as a speculative buy, highlighting a "Buy" rating from Goldman Sachs. He advised against focusing on stock price alone, urging investors to consider the company's fundamentals. Crinetics develops oral drugs for rare hormonal diseases, with its lead candidate in Phase 3 trials.
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral
Goldman Sachs has upgraded its rating for Crinetics Pharmaceuticals, Inc. (CRNX) stock from "neutral" to "buy." This upgrade indicates a more positive outlook on the company's future performance from Goldman Sachs.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress
Crinetics Pharmaceuticals (CRNX) has garnered attention following a Goldman Sachs upgrade and positive Phase 2 data for its drug atumelnant, alongside early revenue from Palsonify. Despite recent stock gains and a Price-to-Book ratio of 5.4x, which is attractive compared to peers but high for the broader US pharmaceutical industry, a discounted cash flow model suggests the stock could be significantly undervalued. Investors are balancing the company's strong pipeline and rare disease focus against limited current revenue and ongoing losses.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress
Crinetics Pharmaceuticals (CRNX) has garnered attention following a Goldman Sachs upgrade, positive Phase 2 data for atumelnant, and early revenue from Palsonify. Despite trading at a higher Price-to-Book ratio compared to the broader US pharmaceuticals industry, a Discounted Cash Flow model suggests the stock could be significantly undervalued. Investors are currently weighing the potential of its development pipeline against current losses and early revenue figures.
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral
Goldman Sachs has upgraded Crinetics Pharmaceuticals, Inc. (CRNX) to a Buy rating from Neutral, with a $67 price target, following positive trial results for atumelnant in congenital adrenal hyperplasia. Concurrently, Citizens analyst Jonathan Wolleben slightly lowered their price target to $105 while maintaining an Outperform rating, based on positive early reception for the company's new drug Palsonify. Wall Street analysts generally hold a bullish outlook on CRNX, with a consensus Strong Buy rating and an average one-year price target of $88.64.
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral
Goldman Sachs has upgraded Crinetics Pharmaceuticals (CRNX) to a "Buy" rating from "Neutral," setting a price target of $67. This upgrade follows positive trial results for atumelnant in congenital adrenal hyperplasia and good early reception for their new drug, Palsonify, for acromegaly, as confirmed by an endocrinologist survey. Wall Street analysts generally maintain a "Strong Buy" consensus with an average target price of $88.64, suggesting significant upside potential.
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral
Goldman Sachs has upgraded Crinetics Pharmaceuticals, Inc. (CRNX) to "Buy" from "Neutral" following promising trial results for its drug atumelnant, which showed a significant reduction in A4 in patients with congenital adrenal hyperplasia. Separately, Citizens analyst Jonathan Wolleben slightly cut the firm’s price target on CRNX but maintained an "Outperform" rating, citing positive early experience with the company's recently launched drug, Palsonify. Wall Street analysts generally maintain a "Strong Buy" consensus rating for CRNX with a substantial upside potential.
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates
Crinetics Pharmaceuticals (CRNX) saw an 18.2% increase in its stock price following a US$350.14 million equity raise, positive preliminary Q4 2025 PALSONIFY revenue of over US$5 million, and promising Phase 2 data for atumelnant. These developments highlight early commercial success for PALSONIFY and clinical advancement for atumelnant, strengthening the company's financial position for future development and commercialization.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" rating for Crinetics Pharmaceuticals (NASDAQ:CRNX), with an average 12-month price target of $80.00. Despite a recent EPS miss and insider selling, institutional investors hold a significant portion of the stock, reflecting continued confidence. The company specializes in developing therapeutics for rare endocrine diseases, with its lead candidate, paltusotine, targeting acromegaly and carcinoid syndrome diarrhea.
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announced inducement grants to 10 new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These grants include non-qualified stock options for 37,575 shares at an exercise price of $53.25 and 25,525 restricted stock units, both vesting over four years. This action aligns with their 2021 Employment Inducement Incentive Award Plan to attract new talent.
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates
Crinetics Pharmaceuticals saw an 18.2% increase in its stock price following a significant US$350.14 million equity raise and positive updates on its products. The company reported over US$5 million in preliminary Q4 2025 revenue for PALSONIFY and positive Phase 2 data for atumelnant, signaling early commercial momentum and clinical progress. While the equity raise strengthens the balance sheet, it also introduces dilution, setting the stage for how investors will weigh early launch execution against ongoing cash burn and repeated equity issuance.
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy
The Goldman Sachs Group has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) from a "neutral" to a "buy" rating, setting a $67 price target, which suggests a potential upside of 25.8%. Despite the upgrade and an overall "Moderate Buy" consensus from analysts, the company recently missed EPS estimates and its revenue was below projections. Insider transactions and institutional investor activity also provide a look into recent stock movements.
10 new Crinetics workers get stock awards vesting over 4 years
Crinetics Pharmaceuticals (CRNX) recently announced inducement equity awards for 10 new non-executive employees, consisting of 37,575 non-qualified stock options and 25,525 restricted stock units (RSUs). These awards, granted under the 2021 Inducement Plan, have an exercise price of $53.25 and vest over four years to align employee incentives with company performance. This move supports the company's ongoing growth, commercialization efforts, and hiring activities.
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals granted non-qualified stock options for 37,575 shares and 25,525 restricted stock units (RSUs) to 10 new non-executive employees on January 10, 2026. These grants, made under the 2021 Employment Inducement Incentive Award Plan, serve as material inducements for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have four-year vesting schedules, with specific exercise prices for the options and annual installments for the RSUs.
